Home / Market News / $PCRX

$PCRX news and market catalysts

The 15 most recent market catalysts affecting $PCRX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

15 catalysts 4 high impact 7 bullish 7 bearish Pharmaceuticals
Nov 10, 2026 Corporate Catalyst Bullish Impact 65
RBC Capital Raises Pacira BioSciences Price Target to $36.50
RBC Capital has raised its price target for Pacira BioSciences (PCRX) from $25.00 to $36.50. This substantial increase reflects a more favorable outlook from the analyst firm regar…
Nov 6, 2026 Corporate Catalyst Bearish Impact 80
Pacira BioSciences Reports Third-Quarter 2026 Financial Results
Pacira BioSciences reported Q3 2026 financial results, showing a 2% year-over-year revenue decline to $176.65 million. This decline is a negative signal, but was partially offset b…
Oct 9, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5
RBC Capital analyst Douglas Miehm has maintained a 'Sector Perform' rating on Pacira BioSciences (PCRX) but significantly raised the price target from $25 to $36.5. This action ind…
Oct 9, 2026 Corporate Catalyst Bearish Impact 60
HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5
HC Wainwright & Co. analyst Douglas Tsao downgraded Pacira BioSciences (PCRX) from a 'Buy' rating to 'Neutral' and lowered the price target from $38 to $36.50. This action signals …
Oct 8, 2026 Corporate Catalyst Bearish Impact 65
Jefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target
Jefferies analyst Glen Santangelo downgraded Pacira BioSciences (PCRX) from a 'Buy' to a 'Hold' rating and lowered the price target to $36. This action signals a less optimistic vi…
Oct 8, 2026 Corporate Catalyst Bearish Impact 55
Needham Downgrades Pacira BioSciences to Hold
Needham analyst Serge Belanger downgraded Pacira BioSciences (PCRX) from a 'Buy' to a 'Hold' rating. This change in analyst sentiment indicates a less optimistic view on the compan…
Oct 8, 2026 Corporate Catalyst Bullish Impact 95
Pacira BioSciences shares are trading higher after the company announced it will be acquired by Viatris.
This headline represents a major corporate catalyst, specifically an acquisition, which typically results in a significant positive movement for the target company's stock (Pacira …
Oct 7, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Pacira BioSciences, Raises Price Target to $31
Truist Securities analyst Les Sulewski has maintained a 'Buy' rating on Pacira BioSciences (PCRX) and raised the price target from $30 to $31. This action signals continued analyst…
Oct 5, 2026 Corporate Catalyst Bullish Impact 75
Pacira BioSciences Announces Exclusive Agreement With Molteni Farmaceutici To Commercialize EXPAREL In Europe; Pacira To Receive Undisclosed Upfront Payment Plus Royalties
This headline represents a significant positive catalyst for Pacira BioSciences. The exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL in Europe opens up a sub…
Sep 23, 2026 Corporate Catalyst Neutral Impact 55
Oppenheimer Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target of $32
Oppenheimer analyst Les Sulewski has initiated coverage on Pacira BioSciences (PCRX) with an 'Outperform' rating and a price target of $32. This is a positive development for PCRX …
Aug 6, 2026 Corporate Catalyst Bullish Impact 75
Pacira Biosciences Publishes 2-Yr Phase 1 Results In Annals Of Rheumatic Diseases For PCRX-201 Gene Therapy In Moderate To Severe Knee Osteoarthritis, Showing Tolerability And Improvements In Pain, Stiffness, And Function
Pacira Biosciences (PCRX) announced the publication of positive two-year Phase 1 clinical trial results for PCRX-201, its gene therapy for knee osteoarthritis. The study, published…
Aug 5, 2026 Corporate Catalyst Bullish Impact 75
Pacira BioSciences shares are trading higher after the company reported better-than-expected Q2 sales results.
The better-than-expected Q2 sales for Pacira BioSciences (PCRX) are a significant positive catalyst, directly impacting the company's stock price upwards. This performance suggests…
Aug 5, 2026 Corporate Catalyst Bearish Impact 85
Pacira BioSciences shares are trading lower after the company lowered its FY2026 sales guidance.
The lowered FY2026 sales guidance for Pacira BioSciences (PCRX) is a direct and significant negative corporate catalyst. This indicates that the company anticipates weaker future r…
Aug 4, 2026 Corporate Catalyst Bearish Impact 75
Pacira BioSciences Lowers FY2026 Sales Guidance from $745.000M-$770.000M to $735.000M-$760.000M vs $766.384M Est
Pacira BioSciences (PCRX) announced a reduction in its FY2026 sales guidance, moving from a range of $745 million-$770 million to $735 million-$760 million. This revised outlook is…
Aug 4, 2026 Corporate Catalyst Bearish Impact 85
Pacira BioSciences Q2 Adj. EPS $0.73 Beats $0.65 Estimate, Sales $192.400M Beat $190.816M Estimate
Pacira BioSciences announced its Q2 earnings, reporting adjusted EPS of $0.73 and sales of $192.4 million, both surpassing analyst consensus estimates. This indicates a stronger-th…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.